Skip to nav Skip to content

Small intestine cancer clinical trials offer participants access to a wide variety of exciting new treatment options, such as innovative surgical techniques, novel radiation therapy delivery methods and more targeted chemotherapy drugs. The main purpose of these studies is to evaluate the effectiveness of a brand-new treatment as compared to the current standard of care. If the results of a clinical trial establish that a new treatment is more effective than the currently available treatments, or equally effective with fewer side effects, the new treatment may become the new standard of care. Every treatment goes through a similar process prior to being made widely available for use in all clinical settings.

Interested in learning more about current clinical trials at Moffitt? One of our clinical trial navigators can help you explore your options and suggest opportunities that may be right for you.
Submit a clinical trials inquiry

Moffitt Cancer Center has a robust portfolio of small intestine cancer clinical trials. At any given time, one or more new therapies are under study, such as:

  • Biological therapy – Substances created by the body or in a laboratory are used to enhance, target or restore the body’s immune system to provide a natural defense against cancer.
  • Radiation therapy with radiosensitizers – Certain drugs, which have been found to make cancer cells more receptive to radiation therapy, are administered in conjunction with radiation therapy to potentially destroy more cancer.
  • Chemotherapy – Drugs injected into a vein or taken by mouth can destroy cancer cells or prevent them from growing, and researchers are continually testing new medications and drug combinations to improve effectiveness and reduce side effects.
  • Surgical approaches – Surgery, which is the most commonly recommended form of treatment for small intestine cancer, may be more effective when performed with certain techniques to help remove (resect) an affected portion of the small intestine or create a path for food to bypass a cancerous obstruction.

As a National Cancer Institute-designated Comprehensive Cancer Center, Moffitt has established an outstanding reputation for excellence in cancer research. As we continue to expand the knowledge base about all forms of cancer, we use clinical trials as a way to translate breakthrough laboratory discoveries into accessible treatment options for current and future cancer patients, improving their survival rate and quality of life.

If you've been diagnosed with small intestine cancer and are interested in clinical trials, our clinical trial navigators can answer your questions. Call call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online.

 

  • Clinical Trials

    CLINICAL TRIAL 21742
    Remote Resistance Exercise Powering Survivors- Gastrointestinal Oncology (Remote REPS-:GI)
    Condition: Gastrointestinal Tumor
    Intervention:

    CLINICAL TRIAL 22002
    A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS
    Condition: Multiple
    Intervention: RMC-6236 ()

    CLINICAL TRIAL 22685
    Phase 1/1B, Multicenter, Open-Label, Study of RMC-9805 in Participants with Advanced KRASG12D-Mutant Solid Tumors
    Condition: Multiple
    Intervention: RMC-6236 (); RMC-9805 ()

    CLINICAL TRIAL 23375
    Phase II Study of NALIRIFOX (Nanoliposomal Irinotecan + Oxaliplatin with Fluorouracil and Folinic Acid) in Advanced Unresectable Small Bowel Tumors
    Condition: Gastrointestinal Tumor
    Intervention: 5-fluorouracil (); Nanoliposomal Irinotecan (); Oxaliplatin (); eloxatin (Oxaliplatin); leucovorin ()

    CLINICAL TRIAL 23480
    A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations
    Condition: Multiple
    Intervention: CGT4859 ()

    CLINICAL TRIAL 23697
    A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
    Condition: Multiple
    Intervention: AMG 510 (Sotorasib); GSK1120212 (Trametinib); Olomorasib (); Sotorasib (); Trametinib (); VVD-159642 ()

    CLINICAL TRIAL 23766
    A First-in-Human Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of FID-022 as Monotherapy in Patients with Advanced Solid Tumors
    Condition: Multiple
    Intervention: FID-022 ()

    CLINICAL TRIAL 23773
    A Phase 1b/2 Study of AZD0120 (also known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B cell Maturation Antigen in Participants with Relapsed or Refractory AL Amyloidosis
    Condition: Malignant Hematology
    Intervention: AZD0120 ()